Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab
| Autor: | Malmberg, Ruben, Zietse, Michiel, Dumoulin, Daphne W, Hendrikx, Jeroen J M A, Aerts, Joachim G J V, van der Veldt, Astrid A M, Koch, Birgit C P, Sleijfer, Stefan, van Leeuwen, Roelof W F * |
|---|---|
| Zdroj: | In The Lancet Oncology December 2022 23(12):e552-e561 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|